Bone Biologics Corp.

As of June 20, 2025, the trend is mildly bullish based on weekly and monthly MACD readings, though daily moving averages are mildly bearish, indicating mixed signals that warrant careful monitoring.

Bone Biologics Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $1 million and a market cap of $2.77 million. Key metrics include a negative P/E ratio, no dividend yield, and a return on equity of -146.99%.

As of Jun 18, Bone Biologics Corp. has a market capitalization of 2.77 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -4.26 million over the latest four quarters. As of Dec 24, the company reported shareholder's funds of 3.48 million and total assets of 3.86 million.